IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

NCT04933799 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

68

Enrollment

OTHER

Sponsor class

Conditions

COVID-19 Pneumonia

Interventions

DRUG: PF-06650833
DRUG: Matching Placebo

Sponsor

Giovanni Franchin, M.D, Ph.D

Collaborators

[object Object]